# Treatment With Infliximab in a Medical Setting (Study P05587)

> **NCT00752622** · PHASE4 · TERMINATED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 100 (actual)

## Conditions studied

- Crohn's Disease

## Interventions

- **BIOLOGICAL:** Infliximab 5 mg/kg
- **BIOLOGICAL:** Infliximab 5 mg/kg every 6 weeks
- **BIOLOGICAL:** Infliximab 7 mg/kg every 8 weeks

## Key facts

- **NCT ID:** NCT00752622
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2008-11
- **Primary completion:** 2010-06
- **Final completion:** 2010-06
- **Target enrollment:** 100 (ACTUAL)
- **Why stopped:** Factors that led to termination: recruitment challenges and a lower incidence of flares than estimated, causing a high risk of the study being underpowered.
- **Last updated:** 2017-04-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00752622

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00752622, "Treatment With Infliximab in a Medical Setting (Study P05587)". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT00752622. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*